EUCTR2013-003643-31-GB进行中（未招募）1 期
Assessing the therapeutic efficacy and safety of an 11ß-hydroxysteroid dehydrogenase type 1 inhibitor (AZD4017) in idiopathic intracranial hypertension (IIH). - Efficacy and safety of 11b-HSD1 inhibitor in IIH
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1.Provision of informed consent prior to any study specific procedures.
- •2.Female patients between 18 and 55 years old
- •3.Diagnosis of IIH by the updated Modified Dandy criteria with acute (<6 months from Neuro-opthalmology diagnosis), active disease (papilloedema (Frisen grade greater than or equal to 1) and significantly raised intracranial pressure >25cmH2O) and normal brain imaging during previous routine diagnostic work up (evaluated by either magnetic resonance venography or computerised tomography with venography).
- •4.Patients must be willing to use one form of highly effective, non-hormonal contraception. This would include a vasectomised partner, tubal occlusion or copper containing IUD – all of which should be used in addition to a barrier contraceptive (condom or diaphragm or cervical/vault caps with spermicidal foam/gel/film/suppository) or abstinence (when this is in line with the preferred and usual lifestyle of the subject). Women should have been stable on their chosen method of birth control for a minimum of 2 months before entering the trial. Patients must agree to undergo a b-hCG blood test at screening and urine testing at all trial visits (including the final follow up visit 4 weeks after discontinuation of study treatment).
- •5. Participants are able to continue other medications to treat their IIH e.g. acetazolamide, diuretics but this dose must remain fixed throughout the study. It would be expected that there would be an equal number in each trial.
- •6.Must be able to understand the consent form and comply with study requirements.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •1.Optic nerve sheath fenestration (as distortion of the optic nerve would prevent accurate assessment of their disease state). Patients who have had previous failed CSF shunting will be eligible for enrolment if they fulfil all other enrolment criteria.
- •2.Abnormal neurological examination (aside from papilloedema and consequent visual loss or VI nerve palsy).
- •3.Subjects with a secondary cause of raised intracranial pressure will be excluded.
- •4.Abnormal cerebrospinal fluid contents (except for that compatible with a traumatic LP).
- •5.Unable to perform a visual field test reliably.
- •General Exclusion Criteria:
- •1.Positive hCG or urine dipstick pregnancy test or planning to conceive.
- •2.Have eGFR calculated by MDRD equation of <60ml/min/1.73m2.
- •3.Have any endocrine disorder, e.g, thyroid dysfunction (potential participants with PCOS will no be excluded as this is a known associated condition).
- •4.Suspicion of or known Gilbert's disease.
- •5.Creatinine kinase >2 x upper limit of normal on 2 consecutive measurements.
- •6.Liver aminotransferases > 2x Upper limit of normal
- •7.Alkaline phosphatases > Upper limit of normal
- •8.Bilirubin (total) > 2 x upper limit of normal
- •9. Must not have donated blood within 2 months of attending the screening
- •visit and avoid donating blood within the following 4 months.
- •10.Patient is, at the time of signing the informed consent, a user of recreational or illicit drugs (including marijuana) or has had a recent history (within the last year) of drug or alcohol abuse or dependence, in the opinion of the investigator.
- •11.Pregnant or breastfeeding mothers, unless willing to discontinue breastfeeding by the baseline visit.
- •12.Have uncontrolled systemic hypertension (BP >160 systolic or >90 diastolic), on 3 successive measurements on the morning of the screening visit.
- •13.Are receiving systemic (including vaginal/rectal) glucocorticoid treatment at the time of the screening visit.
- •14.Are taking any hormone-based medication, including hormone contraceptives, at the time of screening.
- •15.Are taking probenicid at the time of the screening visit.
- •16.Have any screening laboratory abnormality that, in the investigator’s judgement, is considered to be clinically significant or any screening laboratory value which is outside the Sponsor specified ranges at screening; testing may be repeated once to see if the value returns to within the range but any laboratory abnormality must be resolved prior to the baseline visit.
- •17.History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results of the subject’s ability to participate in the study. Specifically, a diagnosis of any inflammatory disorder that might reasonably need treatment with glucocorticoids during the course of the study.
- •18.History or presence of sigificant gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
- •19.Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IP as judged by the investigator.
- •20.Have been involved in the planning and/or conduct of the study
- •21.Participation in another interventional study in the prevous 1 month prior to screening
- •22.Previous randomisation for treatment in the present study.
研究者
相似试验
已完成
4 期
Evaluation of therapeutic efficacy and safety of artesunate-amodiaquine, artemether-lumefantrine and dihydroartemisinine-piperaquine for the treatment of uncomplicated Plasmodium falciparum in Democratic Republic of CongoInfection - Studies of infection and infectious agentsMalariaACTRN12616001423404Ministry of Health534
已完成
2 期
A study on siddha medicine kumaara veeriya kaantha chenduram for anaemiaCTRI/2019/04/018795Ayothidoss Pandithar hospital30
尚未招募
2 期
Evaluation of safety and therapeutic efficacy of siddha drug KANDAAMALAGA ILAKAM in the treatment of Iron deficiency anaemia.CTRI/2018/05/014111Ayothidoss Pandithar Hospital
尚未招募
2 期
VALERGEN-combination of routes- Asthma-Adults-Phase IIAsthmaBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System DiseasesEnvironmental IllnessRPCEC00000298ational Center of Bioproducts (BioCen)180
招募中
1 期
Itolizumab (T1h) combined with insulin in patients with Type I Diabetes MellitusDiabetes Mellitus, Type 1Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System DiseasesDiabetes MellitusType 1 diabetes mellitusRPCEC00000225Center of Molecular Immunology (CIM)40